医药股回吐 石药及药明生物急跌逾6%至7%
医药股今天受压,尤其是药明生物(02269.HK)股价重失20天、250天及10天线,最低见46.8元,现报47.1元,回吐7.1%。高盛本周初发表报告引述药明生物管理层指今年会如期推动80个新项目的目标,但今年利润率或会触底,料明年将可改善,该行指药明生物本季交付若慢于预期,会影响2023财年利润率
药明康德(02359.HK)及药明巨诺(02126.HK)股价各跌3.5%及6%,分别报92.85元及2.49元,均股价跌破10天线。百济神州(06160.HK)失守10天线,最低见113.6元,现报115.2元,回吐6%。
其余蓝筹医药股也全线跌逾2%-6%,石药(01093.HK)沽压最大,股价失守10天线,最低见6.72元,报6.75元,回吐6.3%。
康宁杰瑞制药-B(09966.HK)、信达生物(01801.HK)、腾盛博药(02137.HK)、诺诚健华(09969.HK)、四环药业(00460.HK)、开拓药业(09939.HK)、康方生物(09926.HK)及君实(01877.HK)反复跌逾2%-3.5%。再鼎医药(09688.HK)回吐6.6%报21.1元,股价失守10天线(21.9元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.